poterepatide (HDM-1005) / Huadong Medicine - LARVOL DELTA

Significant weight reduction with improved body composition by HDM1005, a novel long-acting GLP-1R/GIPR dual agonist (EASD 2025) - "Collectively, HDM1005 achieves significant weight loss primarily through fat mass reduction (contribution to total weight loss: 81.58%). Notably, HDM1005 also exhibits promising therapeutic potential for MASH, highlighting its dual benefit in metabolic disease management."

Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Phase Ib Clinical Study of HDM1005 Injection (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study (ADA 2025) - P1 | "HDM1005 was well tolerated, had favorable PK, and led to promising body weight reduction and improvements in OGTT AUC0-2h and lipid profiles. Phase II studies of HDM1005 in obesity and T2DM are currently ongoing."

Clinical • PK/PD data • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Huadong Medicine HDM1005 Injection Approved to Conduct Clinical Trial on OSA and Obesity Patients [Google translation] (new.qq.com) - "According to the latest news from Radar Finance, Huadong Medicine (000963)'s wholly-owned subsidiary Sino-US Huadong received the 'Drug Clinical Trial Approval Notice' approved and issued by the National Medical Products Administration (NMPA) on February 24, 2025, approving the use of HDM1005 injection for clinical trials in obstructive sleep apnea (OSA) and obese or overweight adult patients."

New trial • Obesity • Obstructive Sleep Apnea